Protein-based markers (such as nuclear matrix protein 22 [NMP22]) are currently used in clinical practice,7,9 but the performance is susceptible to benign conditions such as urinary tract infection (UTI) and calculus, and the accuracy is poor in case of LG tumors.10 This evidence concerns the gene NUMA1 and urolithiasis.